The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

Launched by RUIJIN HOSPITAL · Sep 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two imaging techniques, 18F-FDG and 68Ga-FAPI PET/CT scans, to evaluate how well conversion therapy works for patients with gastric cancer that has spread to the lining of the abdomen (known as peritoneal metastasis). The goal is to find out if these scans can help doctors better assess the treatment outcomes and overall prognosis for these patients.

To join the study, participants must be at least 18 years old and have a confirmed diagnosis of gastric adenocarcinoma, without previous surgery to remove the primary cancer or any metastases. They should have peritoneal metastases that require a specific type of diagnostic procedure called laparoscopy, and must be able to walk unaided or with minimal assistance. Participants will be asked to sign a consent form to confirm they understand the study and are willing to participate. Throughout the study, patients can expect to undergo the PET/CT scans and follow a specific treatment and follow-up plan, all while being monitored by the research team. It’s important to note that individuals with other distant metastases, pregnancy, or severe mental health issues may not be eligible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions
• • 2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction
• • 3. Patients voluntarily enrolled in this study by signing an informed consent form
• • 4. Age ≥ 18 years
• • 5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2,
• • 6. Expected life expectancy ≥ 3 months
• • 7. Adequate organ and bone marrow function
• • 8. Willingness to adhere to the study protocol and follow-up programme
• Exclusion Criteria:
• • 1. Signs of distant metastases other than peritoneal metastases at enrolment
• • 2. Pregnant or breastfeeding women.
• • 3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
• • 4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease